Summary
The duration and the potency of the antiCCK activities of loxiglumide given by sc and oral routes were examined in rats. Pancreatic juice flow and protein output in response to an iv bolus injection of cerulein (100 ng/kg body wt) were measured at specified time intervals from 1–12 h after loxiglumide administration. Subcutaneous loxiglumide (10 g/kg body wt) effectively suppressed cerulein-stimulated protein output for 4 h and pancreatic juice volume for 6 h, when total outputs during a 60-min period after cerulein stimulation were compared with the control value without loxiglumide pretreatment. Oral dose of loxiglumide exerted longer-term anti-CCK activity (protein output: 6 h, pancreatic juice: 8 h) than the same sc dose. In addition, oral loxiglumide showed more potent suppression of protein output than the same sc dose at the corresponding time interval. Higher oral dose of loxiglumide (50 mg/kg body wt) caused longer inhibition on both protein (8 h) and pancreatic juice secretion (12 h). These results suggest that the half-life of loxiglumide given by oral route is longer than that by sc route or that the bioavailability of oral loxiglumide is higher than that of sc dose. The present study demonstrates that loxiglumide, given either by sc or by oral route, has long duration of action in antagonizing responses to exogenously administered cerulein.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jensen RT, Murphy RB, Trampota M, Schneider LH, Jones SW, Howard JM, Gardner JD. Proglumide analog: potent cholecystokinin receptor anatogonist.Am J Physiol 1985; 249: G214-G220.
Makovec F, Chiste R, Bani M, Pacini MA, Setnikar I, Rovati LA. New glutaramic acid derivatives with potent competitive and specific cholecystokinin-antagonistic activity.Arzneim-Forsch Drug Res 1985; 35: 1048–1051.
Evans BE, Bock MG, Rittle KE, DiPardo RM, Whitter WL, Veber DF, Anderson PS, Freidinger RM. Design of potent, orally effective, nonpetide antagonists of the peptide hormone cholecystokinin.Proc Natl Acad Sci USA 1986; 83: 4918–4922, 1986.
Chang RSL, Lotti VJ. Biochemical and pharmacologic characterization of an extremely potent and selective nonpeptide cholecystokinin antagonists.Proc Natl Acad Sci USA 1986; 83: 4923–4926.
Hajri, A, Aprahamian M, Damge C. Effect of a new CCK-receptor antagonist, CR 1409, on pancreatic growth induced by cerulein, CCK-8, bombesin and gastrin-releasing peptide in the rat.Digestion 1989; 43: 66–72.
Schmidt WE, Choudhury AR, Siegel EG, Loser C, Conlon JM, Folsch UR, Creutzfeldt W. CCK-antagonist L-364, 718 influences on rat pancreatic growth induced by cerulein and bombesin-like peptides.Regul Pep. 1989; 24: 67–79; 1989.
Takacs T, Pap A. Perspectives of CCK antagonists in pancreatic research Part 2. Experimental studies.Int J Pancreatol 1991; 10: 1–8
Rovati LC. Perspectives of CCK antagonist in pancreatic research and clinical studies.Int J Pancreatol 1991; 8: 215–226.
Otsuki M, Tani S, Okabayashi Y, Nakamura T, Fuji M, Fujisawa T, Baba S, Itoh H. Effect of a new cholecystokinin receptor antagonist CR1392 on cerulein-induced acute pancreatitis in rat.Pancreas 1988; 4: 237–243.
Silverman H, Ilardi C, Bank S, Kranz V, Lendvai S. Effect of the cholecytoskinin receptor antagonist L-364, 718 on experimental pancreatitis in mice.Gastroenterology 1989; 96: 186–192.
Tani S, Okabayashi Y, Nakamura T, Fuji M, Itoh H, Otsuki M. Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models.Pancreas 1990; 5: 284–290.
Niederau C, Liddle RA, Ferrell LD, Grendell JH. Bene-ficial effects of cholecystokinin receptor blockade and inhibition of proteolytic enzyme activity in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis.J Clin Invest 1986; 78: 1056–1063.
Wisner JR Jr, Renner IG. Asperlicin, a nonpeptidal cholecystokinin receptor antagonist, attenuate sodium taurocholate-induced acute pancreatitis in rat.Pancreas 1988; 3: 174–179.
Zucher KA, Adrian TE, Bilchik AJ, Modlin IM. Effects of the CCK receptor antagonist L-364,718 on pancreatic growth in adult and developing animals.Am J Physiol 1989; 257: G511-G516.
Wisner JR Jr, Ozawa S, Xue B-G, Renner IG. Chronic administration of a potent cholecystokinin receptor antagonist, L-364,718, fail to inhibit pancreas growth in preweaning rats.,Pancreas 990; 5: 434–438
Takacs T, Nagy I, Pap A, Varro V. The anti-CCK effect of glutaramic acid derivatives in the anesthetized and conscious rats.Pancreas 1988; 3: 465–470.
Takacs T, Nagy I, Pap A, Varro V. The effect of CR 1409, a potent CCK recetpor antagonist, on basal and stimulated pancreatic secretion in rat.Pancreas 1990; 5: 60–64.
Otsuki M, Fuji M, Nakamura T, Okabayashi Y, Tani S, Fujiawa T, Koide M, Baba S. Loxiglumide: a new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.Dig Dis Sci 1989; 34: 857–864.
Shiratori K, Chen YF, Chey WY, Lee KY, Chang T-M. Mechanism of increased exocrine pancreatic secretion in pancreatic juice-diverted rat.Gastroenterology 1986; 91: 1171–1178.
Folsch UR, Cantor P, Wilms HM, Schafmayer A, Becker HD, Creutzfeldt W. Role of cholecystokinin in the negative feedback control of pancreatic enzyme secretion in conscious rats.Gastroenterology 1987; 92: 449–458.
Sun G, Lee KY, Chang T-M, Chey WY. Effect of pancreatic juice diversion on secretin release in rats.Gastroenterology 1989; 96: 1173–1179.
Guan D, Maouyo D, Taylor IL, Gettys TW, Greely Jr GH, Morisset J. Peptide-YY, a new partner in the negative feed-back control of pancreatic secretion.Endocrinology 1991; 128: 911–916.
Miyasaka K, Funakoshi A, Miyasaki K, Kitani K. Release of pancreatic polypeptide and its mechanism in luminal feedback regulation in the conscious rat.Digestion 1989; 43: 73–80.
Setnikar I, Chiste R, Makovec F, Rovati LC, Warrington SJ. Pharmacokinetics of loxiglumide after single intravenous or oral dose in humans.Arzneim-Forsch Drug Res 1988; 38: 716–720.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent.J Biol Chem 1951; 193: 265–267.
Setnikar I, Bani M, Cereda R, Chiste R, Makovec F, Pacini MA, Revel L. Anticholecystokinin activities of loxiglu-mide.Arzneim-Forsch Drug Res 1987; 37: 1168–1171.
Liddle RA, Morita ET, Conrad CK, Williams JA. Regulation of gastric emptying in human by cholecystokinin.J Clin Invest 1986; 77: 992–996.
Meyer BM, Werth BA, Beglinger C, Hildebrand P, Jansen JBMJ, Zach D, Rovati LC, Stalder GA. Role of cholecystokinin in regulation of gastrointestinal motor function.Lancet 1989; 2: 12–15.
Fried M, Schwizer W, Beglinger C, Keller V, Jansen JB, Lamer CB. Physiological role of cholecystokinin on postprandial insulin secretion and gastric meal emptying in man. Studies with the cholecyatokinin receptor antagonist loxiglumide.Diabetologia 1991; 34: 721–726
Rosewicz S, Lewis LD, Wang X-Y, Liddle RA, Logsdon CD. Pancreatic digestive enzyme gene expression: effects of CCK and soybean trypsin inhibitor.Am J Physiol 1989; 256: G733-G738.
Rivard N, Guan D, Maouyo D, Grondin G, Berube FL, Morisset J. Endogenous cholecyatokinin release responsible for pancreatic growth observed following pancreatic juice diversion.Endocrinology 1991; 129: 2867–2874.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Watanabe, N., Otsuki, M. Duration and potency of anticholecystokinin action of subcutaneous and oral loxiglumide on cerulein-stimulated pancreatic exocrine secretion. Int J Pancreatol 13, 129–137 (1993). https://doi.org/10.1007/BF02786081
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02786081